Yarrow Bioscience (YARW) FCF Margin (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly FCF Margin came in at 4745.35% in Q1 2026, up 98515.0% YoY from N/an in Q1 2025, and up 56.22% on a QoQ basis from 10839.0% in Q2 2025.
Yarrow Bioscience (YARW) FCF Margin (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of FCF Margin data on file, last reported at 4745.35% in Q1 2026.
- Quarterly FCF Margin rose 98515.0% year-over-year to 4745.35% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5624.95% (up 59632.0% YoY) and the FY2025 annual result came in at 5811.23%, up 100657.0% from the prior year.
- FCF Margin improved to 4745.35% in Q1 2026, from 10839.0% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 4266.47% in Q3 2022 to a low of 16589.66% in Q4 2022.
- A 5-year average of 7349.83% and a median of 6527.78% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin plunged 1278233 bps — and 2023, when it soared 983044 bps.
- Tracing YARW's FCF Margin over 5 years: stood at 16589.66% in 2022, then jumped by 59 bps to 6759.21% in 2023, then tumbled by 60 bps to 10842.17% in 2024, then gained by 0 bps to 10839.0% in 2025, then jumped by 56 bps to 4745.35% in 2026.
- The last three FCF Margin figures came in at 4745.35% (Q1 2026), 10839.0% (Q2 2025), and 5730.5% (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 70.82% |
| 10 | Yarrow Bioscience | 31.22 Mn | 8.30 Mn | - | -2,000.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,000.00% |
| Mar 31, 2026 | -4,745.35% |
| Jun 30, 2025 | -10,839.00% |
| Mar 31, 2025 | -5,730.50% |
| Dec 31, 2024 | -10,842.17% |
| Sep 30, 2024 | -7,033.06% |
| Jun 30, 2024 | -4,283.84% |
| Mar 31, 2024 | -7,981.00% |
| Dec 31, 2023 | -6,759.21% |
| Sep 30, 2023 | -4,519.30% |
| Jun 30, 2023 | -9,574.00% |
| Mar 31, 2023 | -5,478.00% |
| Dec 31, 2022 | -16,589.66% |
| Sep 30, 2022 | -4,266.47% |
| Jun 30, 2022 | -6,527.78% |
| Mar 31, 2022 | -5,078.09% |
| Dec 31, 2021 | -3,807.33% |
| Sep 30, 2021 | -12,932.33% |
| Jun 30, 2021 | -5,350.85% |
| Mar 31, 2021 | -5,281.30% |